Trials should test combinations... Dr Dreicer on PC trial endpoints
OncLive today 3/18/13 Dr Robert Dreicer on future endpoints of prostate cancer clinical trials. Interesting read...
“Can you continue to anticipate, in an era where multiple trials are going to be done with multiple overlapping mechanisms, that we can still use overall survival as an endpoint?” he asked. “The likelihood, as we begin to start thinking about these new combinations, is that that’s not going to be acceptable.”
haven't listened to Dreicer's comments yet but trials have been using PFS with an eye on "quality-of-life" for awhile now, recognizing OS can require lengthy time periods to achieve. not that OS will not continue to be somewhat of a gold-standard for establishing efficacy over the long haul - some drugs (e.g., velcade) are approved without OS results.